When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...

Q2 earnings and new guidance put Bio-Rad Laboratories in focus Bio-Rad Laboratories (BIO) drew investor attention after ...

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy’s resilience and ...

Have you assessed how the international operations of Bio-Rad Laboratories (BIO) performed in the quarter ended June 2026? For this maker of instruments used in biomedical research, possessing an ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad Laboratories ( (BIO)) just unveiled an update. Bio-Rad Laboratories reported first-quarter 2026 results on April 30, 2026, showing total net sales of $592.1 million, up 1.1% year-on-year, but ...

Bio-Rad Laboratories is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) ...